June 15, 2023 Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
June 12, 2023 Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
May 12, 2023 Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 11, 2023 Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
January 17, 2023 Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
December 19, 2022 Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones